No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds
2012 (English)In: Journal of Cerebral Blood Flow and Metabolism, ISSN 0271-678X, E-ISSN 1559-7016, Vol. 32, no 8, 1468-1471 p.Article in journal (Refereed) Published
Decreased blood-brain barrier P-glycoprotein (Pgp) function has been shown in Alzheimer's disease (AD) patients using positron emission tomography (PET) with the radiotracer (R)-[C-11] verapamil. Decreased Pgp function has also been hypothesized to promote cerebral amyloid angiopathy (CAA) development. Here, we used PET and (R)-[C-11] verapamil to assess Pgp function in eighteen AD patients, of which six had microbleeds (MBs), presumably reflecting underlying CAA. No differences were found in binding potential and nonspecific volume of distribution of (R)-[C-11] verapamil between patient groups. These results provide no evidence for additional Pgp dysfunction in AD patients with MBs.
Place, publisher, year, edition, pages
2012. Vol. 32, no 8, 1468-1471 p.
Alzheimer's disease, blood-brain barrier, cerebral amyloid angiopathy, P-glycoprotein, positron emission tomography, (R)-[C-11]verapamil
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-181876DOI: 10.1038/jcbfm.2012.64ISI: 000307099400003OAI: oai:DiVA.org:uu-181876DiVA: diva2:557960